Aptinyx Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 40

Employees
  • Stock Symbol
  • APTX

Stock Symbol
  • Share Price
  • $0.53

  • (As of Tuesday Closing)

Aptinyx General Information

Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Contact Information

Website
www.aptinyx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 909 Davis Street
  • Suite 600
  • Evanston, IL 60201
  • United States
+1 (847) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aptinyx Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.53 $0.55 $0.36 - $3.76 $37.2M 67.7M 567K -$1.18

Aptinyx Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 61,746 69,549 115,058 971
Revenue 0 1,000 1,564 3,669
EBITDA (80,335) (74,286) (49,553) (56,955)
Net Income (80,487) (74,886) (50,053) (57,410)
Total Assets 106,654 114,928 150,606 106,479
Total Debt 24,292 14,155 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aptinyx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.

Request a free trial

Aptinyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.

Request a free trial

Aptinyx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
Drug Discovery
Evanston, IL
40 As of 2021
00000
00000000 00000

00000

fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia des
0000000000000
Cambridge, MA
000 As of 0000
00000
000000&0

000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aptinyx Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agios Formerly VC-backed Cambridge, MA 000 00000 000000&0
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
00000000 000000000 Corporation South San Francisco, CA 00 000.00 000000000 000.00
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 000000&0
You’re viewing 5 of 43 competitors. Get the full list »

Aptinyx Patents

Aptinyx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210322393-A1 Methods of treating cognitive impairment associated with neurodegenerative disease Pending 04-Dec-2019 00000000000
US-20210139489-A1 Methods of treating painful diabetic peripheral neuropathy Pending 11-Nov-2019 000000000
US-20210308101-A1 Methods of treating fibromyalgia Pending 11-Nov-2019 0000000000
AU-2019215058-A1 Spiro-lactam nmda receptor modulators and uses thereof Pending 31-Jan-2018 0000000000
CA-3089561-A1 Spiro-lactam nmda receptor modulators and uses thereof Pending 31-Jan-2018 C07D471/10
To view Aptinyx’s complete patent history, request access »

Aptinyx Executive Team (8)

Name Title Board Seat Contact Info
Ashish Khanna Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Patricia Adams Senior Vice President, Human Resources and Administration
Amin Khan Ph.D Vice President, Chemistry Research & Development
You’re viewing 3 of 8 executive team members. Get the full list »

Aptinyx Board Members (16)

Name Representing Role Since
Adam Koppel Ph.D Bain Capital Board Member 000 0000
Andy Kidd Aptinyx Board Member 000 0000
Gilmore O'Neill Self Board of Director 000 0000
Henry Gosebruch Self Board Member 000 0000
Norbert Riedel Ph.D Aptinyx Chairman & Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Aptinyx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aptinyx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.

Request a free trial